Geron 10-Q: Q3 Profit on $60.1M RYTELO Sales, $339.4M Cash After IMpactMF Wind-Down
GERN sits 27% above its 52-week low of $0.84 on elevated volume (2.3× avg).
Summary
Geron posted Q3 2026 net income of $1.4 million on RYTELO revenue of $60.1 million, up 27% year over year, with $339.4 million in cash and securities. The profit comes as the company becomes wholly dependent on lower-risk MDS after discontinuing its myelofibrosis trial.
Key Events · Earnings and Guidance · GERN
-
First Quarterly Profit on RYTELO Growth
Q3 2026 net income was $1.4 million versus a $18.4 million loss a year ago, as net product revenue rose to $60.1 million from $47.2 million.
-
Cash Falls to $339.4 Million
Cash, restricted cash, equivalents and marketable securities totaled $339.4 million at September 30, 2026, down from $401.1 million at December 31, 2025; nine-month operating cash use was $68.5 million.
-
IMpactMF Discontinuation Leaves One Product
After the October 2026 decision to stop the Phase 3 IMpactMF trial, Geron will not pursue the relapsed/refractory myelofibrosis indication and remains wholly dependent on RYTELO in lower-risk MDS.
-
$150M ATM Remains Untapped
The February 27, 2026 sales agreement with TD Cowen allows up to $150 million of common stock sales at a commission of up to 2.5%; no shares have been sold under it.
Analysis · GERN · Life Sciences
Geron's first quarterly profit rests on a single product. RYTELO net revenue of $60.1 million in Q3 was up 27% from $47.2 million a year earlier, and cost cuts from the December 2025 workforce reduction turned a $13.9 million operating loss a year ago into $5.8 million of operating income. The catch is that the October 28 discontinuation of the Phase 3 IMpactMF trial removes the relapsed/refractory myelofibrosis indication entirely, so the company is now wholly dependent on lower-risk MDS. Cash, equivalents and marketable securities of $339.4 million (down from $401.1 million at year-end) plus roughly $68.5 million of nine-month operating cash burn leaves a runway that management calls sufficient for the foreseeable future, but the $150 million TD Cowen at-the-market program remains an overhang with no shares sold to date. The securities class action survived a motion to dismiss on August 13, 2026 and is now in discovery, an unquantified cost.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GERN was trading at $1.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $693.9M. The 52-week trading range was $0.84 to $2.01. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.